Full View

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination

A Tscherne, JH Schwarz, C Rohde… - Proceedings of the …, 2021 - National Acad Sciences
Severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) has emerged as
the infectious agent causing the pandemic coronavirus disease 2019 (COVID-19) with …
被引用次数：84 相关文章

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination

A Tscherne, J Schwarz, C Rohde… - Proceedings of the …, 2021 - elib.tiho-hannover.de
Severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) has emerged as
the infectious agent causing the pandemic coronavirus disease 2019 (COVID-19) with …

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination

A Tscherne, JH Schwarz, C Rohde… - Proceedings of the …, 2021 - ui.adsabs.harvard.edu
The highly attenuated vaccinia virus MVA is licensed as smallpox vaccine; as a vector it is a
component of the approved adenovirus-MVA-based prime-boost vaccine against Ebola …

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination

A Tscherne, SJ Hendrik, G Kalodimou… - Proceedings of the …, 2021 - elibrary.ru
ACKNOWLEDGMENTS. We thank Patrizia Bonert, Ursula Klostermeier, Johannes Döring,
and Axel Groß for expert help in animal studies. We thank Nico Becker, Astrid Herwig, and …

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccination

A Tscherne, JH Schwarz, C Rohde, A Kupke… - 2021 - pesquisa.bvsalud.org
The severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) has emerged
as the infectious agent causing the pandemic coronavirus disease 2019 (COVID-19) with …

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination

A Tscherne, JH Schwarz, C Rohde, A Kupke… - Proceedings of the …, 2021 - JSTOR
Severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) has emerged as
the infectious agent causing the pandemic coronavirus disease 2019 (COVID-19) with …

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination

A Tscherne, JH Schwarz, C Rohde, A Kupke… - Proceedings of the …, 2021 - cir.nii.ac.jp
抄録< jats: title> Significance</jats: title>< jats: p> The highly attenuated vaccinia virus MVA
is licensed as smallpox vaccine; as a vector it is a component of the approved adenovirus …

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccination

A Tscherne, JH Schwarz, C Rohde, A Kupke… - bioRxiv, 2021 - biorxiv.org
The severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) has emerged
as the infectious agent causing the pandemic coronavirus disease 2019 (COVID-19) with …
[HTML] europepmc.org

[HTML][HTML] Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccination

A Tscherne, JH Schwarz, C Rohde, A Kupke… - 2021 - europepmc.org
The severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) has emerged
as the infectious agent causing the pandemic coronavirus disease 2019 (COVID-19) with …

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination

A Tscherne, JH Schwarz, C Rohde… - Proceedings of the …, 2021 - pubmed.ncbi.nlm.nih.gov
Severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) has emerged as
the infectious agent causing the pandemic coronavirus disease 2019 (COVID-19) with …